Caterpillar Inc vs Summit Therapeutics Inc — how do they compare? Caterpillar Inc trades at $866.79 (market cap $387.68B), while Summit Therapeutics Inc trades at $15.29 (market cap $12.06B). The key difference: Caterpillar Inc is far larger — about 32.1× Summit Therapeutics Inc's market cap, and Caterpillar Inc pays a 0.77% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CAT | SMMT | |
|---|---|---|
Market Cap | $387.68B | $12.06B |
Sector | Industrials | Health |
52-Week High | $1.06K | $26.98 |
52-Week Low | $407.79 | $12.55 |
Enterprise Value | $426.11B | $11.39B |
Dividend Yield | 0.77% | — |
Signals from Pluang's Aura AI — not financial advice
Caterpillar (CAT) trades at $837.58, down 0.55% on the day, with a bearish technical signal but strong fundamental performance. Recent quarters have consistently beaten EPS estimates, with Q2 2026 EPS of $8.17 surpassing the $6.22 expectation. Revenue growth is supported by AI data center demand, contributing to a robust $67.59B in 2025 revenue. The stock is near key support at $831, with resistance at $850.
Outlook remains positive due to strong earnings momentum and AI-driven infrastructure demand, though elevated valuation ratios (P/E of 36.32) pose a risk. Analyst consensus is bullish with a $1,010 price target, but investors should monitor macroeconomic pressures and competitive threats. The dividend history and cash flow stability add defensive appeal.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Trailing returns across standard periods
Latest headlines on both assets
Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.
Read more on CAT →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →